{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T04:08:53Z","timestamp":1789186133206,"version":"build-2803163510"},"reference-count":55,"publisher":"Pharmaceutical Society of Japan","issue":"9","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Biological &amp; Pharmaceutical Bulletin","Biol. Pharm. Bull."],"published-print":{"date-parts":[[2026,9,10]]},"DOI":"10.1248\/bpb.b26-00220","type":"journal-article","created":{"date-parts":[[2026,9,9]],"date-time":"2026-09-09T22:11:39Z","timestamp":1788991899000},"page":"1482-1490","source":"Crossref","is-referenced-by-count":0,"title":["Critical Medicines Lists in Japan and the European Union: Insights into Supply Resilience and Policy Priorities"],"prefix":"10.1248","volume":"49","author":[{"given":"Ken-ichi","family":"Izutsu","sequence":"first","affiliation":[{"name":"School of Pharmacy, International University of Health and Welfare, 4\u20133 Kozunomori, Narita, Chiba 286\u20138686, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shoto","family":"Sasaki","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International University of Health and Welfare, 852 Hatakeda, Narita, Chiba 286\u20138520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rin","family":"Kondo","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International University of Health and Welfare, 852 Hatakeda, Narita, Chiba 286\u20138520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen","family":"Namiki","sequence":"additional","affiliation":[{"name":"School of Pharmacy, International University of Health and Welfare, 852 Hatakeda, Narita, Chiba 286\u20138520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hideaki","family":"Uzawa","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, International University of Health and Welfare Narita Hospital, 852 Hatakeda, Narita, Chiba 286\u20138520, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroaki","family":"Mamiya","sequence":"additional","affiliation":[{"name":"College of Pharmaceutical Sciences, Ritsumeikan University, 1\u20131\u20131 Noji-higashi, Kusatsu, Shiga 525\u20138577, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"163","reference":[{"key":"1","unstructured":"1) FDA. \u201cDrug shortages: Root causes and potential solutions.\u201d: \u2039https:\/\/www.fda.gov\/drugs\/drug-shortages\/report-drug-shortages-root-causes-and-potential-solutions\u203a, accessed 8 April, 2026."},{"key":"2","unstructured":"2) Critical Medicines Alliance. \u201cStrategic Report of the Critical Medi-cines Alliance.\u201d: \u2039https:\/\/health.ec.europa.eu\/document\/download\/3da9dfc0-c5e0-4583-a0f1-1652c7c18c3c_en?filename=hera_cma_strat-report_en.pdf\u203a, accessed 8 April, 2026."},{"key":"3","unstructured":"3) Sakamaki H. International efforts to ensure stable supply of pharmaceuticals. <i>Kokusai Iyaku Joho (International Pharmaceutical Information)<\/i>, <b>1157<\/b>, 18\u201321 (2020)."},{"key":"4","unstructured":"4) Japan Association of Medical Sciences (JAMS). \u201cProposal on the Stable Supply of Medicines.\u201d: \u2039https:\/\/files.jmsf.or.jp\/uploads\/medium\/file\/309\/20240613112246.pdf\u203a, accessed 8 April, 2026."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5) Casiraghi G, Schweitzer F, Verginer L. Supply-chain vulnerabilities in critical medicines: a persistent risk to pharmaceutical security. <i>Science<\/i>, <b>389<\/b>, 886\u2013888 (2025).","DOI":"10.1126\/science.adx0871"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6) Riela S. Securing Europe\u2019s lifelines: The new strategy for critical medicines. <i>European View<\/i>, <b>24<\/b>, 290\u2013299 (2025).","DOI":"10.1177\/17816858251380915"},{"key":"7","unstructured":"7) FDA. \u201cDrug and biologic essential medicines, medical countermeasures, and critical inputs.\u201d: \u2039https:\/\/www.fda.gov\/media\/143406\/download?attachment\u203a, accessed 8 April, 2026."},{"key":"8","unstructured":"8) MHLW. \u201cList and categorization of drugs for stable supply (revised 1 October, 2021).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/10807000\/000785498.pdf\u203a, accessed 8 April, 2026."},{"key":"9","unstructured":"9) MHLW. \u201cSelection of drugs for stable supply: materials for the sub-committee on rapid and stable supply of pharmaceuticals (27 October, 2025).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/10808000\/001586777.pdf\u203a, accessed 8 April, 2026."},{"key":"10","unstructured":"10) EMA. \u201cQuestions and answers on the Union list of critical medicines.\u201d: \u2039https:\/\/www.ema.europa.eu\/en\/documents\/other\/questions-answers-union-list-critical-medicines_en.pdf\u203a, accessed 8 April, 2026."},{"key":"11","unstructured":"11) EMA. HMA, EC. \u201cMethodology to identify critical medicines for the Union List of Critical Medicines.\u201d: \u2039https:\/\/www.ema.europa.eu\/en\/documents\/other\/methodology-identify-critical-medicines-union-list-critical-medicines_en.pdf\u203a, accessed 8 April, 2026."},{"key":"12","unstructured":"12) EMA. \u201cUnion list of critical medicines\u2014version 2.\u201d: \u2039https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/post-authorisation\/medicine-shortages-availability-issues\/availability-medicines-during-crises\/union-list-critical-medicines\u203a, accessed 8 April, 2026."},{"key":"13","unstructured":"13) EFPIA. \u201cMedicine Shortages EFPIA Proposal for Action.\u201d: \u2039https:\/\/www.efpia.eu\/media\/adnjlfjd\/medicine-shortages-efpia-proposal-for-action.pdf\u203a, accessed 8 April, 2026."},{"key":"14","doi-asserted-by":"crossref","unstructured":"14) Kawano M, Kojima A, Maeda H. Comparison of national lists of essential medicine among Japan, the United States of America, the European Union, the World Health Organization, Thailand, and China. <i>Asian Pac. J. Health Econ.<\/i>, <b>8<\/b>, 2025.03 (2025).","DOI":"10.6011\/apj.2025.03"},{"key":"15","unstructured":"15) WHO Collaborating Centre for Drug Statistics Methodology. \u201cATC\/DDD Index 2025.\u201d: \u2039https:\/\/atcddd.fhi.no\/atc_ddd_index\/\u203a, accessed 8 April, 2026."},{"key":"16","unstructured":"16) MHLW. \u201cSelection of drugs for stable supply: materials for the sub-committee on rapid and stable supply of pharmaceuticals (August 27, 2025).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/10808000\/001548778.pdf\u203a, accessed 8 April, 2026."},{"key":"17","unstructured":"17) MHLW. \u201cImplementation of the partial amendment act (Provisions re-lated to ensuring a stable supply of supply-secured pharmaceuticals andimportant supply-secured pharmaceuticals).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/001626664.pdf\u203a, accessed 8 April, 2026."},{"key":"18","unstructured":"18) FDA. \u201cDrugs@FDA: FDA-Approved Drugs.\u201d: \u2039https:\/\/www.accessdata.fda.gov\/scripts\/cder\/daf\/index.cfm\u203a, accessed 8 April, 2026."},{"key":"19","unstructured":"19) Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, Japanese Society for Clinical Microbiology, and Japanese Society for Infection Prevention and Control. \u201cFour societies\u2019 jointstatement on ensuring stable supply of antimicrobial agents: to secure the availability of life-saving drugs.\u201d: \u2039https:\/\/www.kansensho.or.jp\/uploads\/files\/topics\/2019ncov\/covid19_4seimei_220803.pdf\u203a, accessed 8 April, 2026."},{"key":"20","unstructured":"20) MHLW. \u201cConcepts for the selection and categorization of drugs forstable supply (5th Meeting on stable supply of pharmaceuticals).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/10807000\/000758411.pdf\u203a, accessed 8 April, 2026."},{"key":"21","doi-asserted-by":"crossref","unstructured":"21) Izutsu K, Ando D, Morita T, Abe Y, Yoshida H. Generic drug shortage in Japan: GMP noncompliance and associated quality issues. <i>J. Pharm. Sci.<\/i>, <b>112<\/b>, 1763\u20131771 (2023).","DOI":"10.1016\/j.xphs.2023.03.006"},{"key":"22","unstructured":"22) MHLW. \u201cEnsuring stable supply of prescriptionpharmaceuticals.\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/11121000\/001340513.pdf\u203a, accessed 8 April, 2026."},{"key":"23","doi-asserted-by":"crossref","unstructured":"23) Mamiya H, Izutsu K, Mitani D. Draft guideline for industry to manage drug shortages in Japan. <i>Ther. Innov. Regul. Sci.<\/i>, <b>58<\/b>, 1023\u20131026 (2024).","DOI":"10.1007\/s43441-024-00678-7"},{"key":"24","unstructured":"24) MHLW. \u201cAct on securing quality, efficacy and safety of products in-cluding pharmaceuticals and medical devices (effective June 1, 2025).\u201d: \u2039https:\/\/laws.e-gov.go.jp\/law\/335AC0000000145\u203a, accessed 8 April, 2026."},{"key":"25","unstructured":"25) MHLW. \u201cMeeting materials: review of stable supply medicines (18thMeeting on measures to ensure the stable supply of prescription drugs).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/10807000\/001333722.pdf\u203a, accessed 8 April, 2026."},{"key":"26","doi-asserted-by":"crossref","unstructured":"26) Matsumoto T. For the stable supply of antimicrobial agents. <i>Journal of the Japanese Society of Internal Medicine<\/i>, <b>113<\/b>, 1433\u20131438 (2024).","DOI":"10.2169\/naika.113.1433"},{"key":"27","unstructured":"27) MHLW. \u201cPolicy on measures to ensure the stable supply of antimicro-bial products.\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/001039660.pdf\u203a, accessed 8 April, 2026."},{"key":"28","unstructured":"28) FDA. \u201cCriteria for identifying human drug and biologic essential med-icines, medical countermeasures, and critical inputs for the list described in Section 3(c) of the Executive Order (EO) 13944.\u201d: \u2039https:\/\/www.fda.gov\/media\/143407\/download?attachment\u203a, accessed 8 April, 2026."},{"key":"29","unstructured":"29) Administration for Strategic Preparedness and Response (ASPR) and Advanced Regenerative Manufacturing Institute (ARMI). \u201cEssential Medicines Supply Chain and Manufacturing ResilienceAssessment.\u201d: \u2039https:\/\/www.armiusa.org\/wp-content\/uploads\/2022\/05\/ARMIEssentialMedicinesSupplyChainReport_May2022.pdf\u203a, accessed 8 April, 2026."},{"key":"30","unstructured":"30) The White House. \u201cChain Resilience by Filling the Strategic Active Pharmaceutical Ingredients Reserve.\u201d: \u2039https:\/\/www.whitehouse.gov\/fact-sheets\/2025\/08\/fact-sheet-president-donald-j-trump-ensures-american-pharmaceutical-supply-chain-resilience-by-filling-the-strategic-active-pharmaceutical-ingredients-reserve\/\u203a, accessed 8 April, 2026."},{"key":"31","unstructured":"31) USP. \u201c2024-2025 Vulnerable Medicines List for the United States: A data-based approach to identify risks and enable interventions to increasereliability of supply.\u201d: \u2039https:\/\/www.usp.org\/sites\/default\/files\/usp\/document\/supply-chain\/2024-2025_vulnerable-medicines-list.pdf\u203a, accessed 8 April, 2026."},{"key":"32","unstructured":"32) Chapman S, Dedet G, Lopert R. \u201cShortages of medicines in OECDcountries.\u201d: \u2039https:\/\/www.oecd.org\/content\/dam\/oecd\/en\/publications\/reports\/2022\/03\/shortages-of-medicines-in-oecd-countries_4d5bc718\/b5d9e15d-en.pdf\u203a, accessed 8 April, 2026."},{"key":"33","unstructured":"33) WHO. \u201cWHO Model List of Essential Medicines - 23rd list, 2023\u201d: \u2039https:\/\/iris.who.int\/bitstream\/handle\/10665\/371090\/WHO-MHP-HPS-EML-2023.02-eng.pdf?sequence=1\u203a, accessed 8 April, 2026."},{"key":"34","doi-asserted-by":"crossref","unstructured":"34) Piggott T, Moja L, Huttner B, Okwen P, Raviglione MCB, Kredo T, Sch\u00fcnemann HJ. WHO Model list of essential medicines: visions for the future. <i>Bull. World Health Organ.<\/i>, <b>102<\/b>, 722\u2013729 (2024).","DOI":"10.2471\/BLT.24.292359"},{"key":"35","doi-asserted-by":"crossref","unstructured":"35) Persaud N, Jiang M, Shaikh R, Bali A, Oronsaye E, Woods H, Drozdzal G, Rajakulasingam Y, Maraj D, Wadhawan S, Umali N, Wang R, McCall M, Aronson JK, Pl\u00fcddemann A, Moja L, Magrini N, Heneghan C. Comparison of essential medicines lists in 137 countries. <i>Bull. World Health Organ.<\/i>, <b>97<\/b>, 394\u2013404C (2019).","DOI":"10.2471\/BLT.18.222448"},{"key":"36","unstructured":"36) Ministry of Food and Drug Safety (MFDS). \u201cNational essential medi-cines.\u201d: \u2039https:\/\/www.mfds.go.kr\u203a, accessed 8 April, 2026."},{"key":"37","unstructured":"37) Health Canada. \u201cTier 3 drug shortages.\u201d: \u2039https:\/\/www.canada.ca\/en\/health-canada\/services\/drugs-health-products\/drug-products\/drug-shortages\/tier-3-shortages.html#wb-auto-4\u203a, accessed 8 April, 2026."},{"key":"38","doi-asserted-by":"crossref","unstructured":"38) Kinoshita S, Kishimoto T. Challenges introduced by Japan\u2019s drug pricing policy. <i>Lancet Reg. Health West. Pac.<\/i>, <b>51<\/b>, 101212 (2024).","DOI":"10.1016\/j.lanwpc.2024.101212"},{"key":"39","unstructured":"39) Sugihara H. Challenges and future initiatives for iodine contrast agents. <i>JCR News<\/i>, <b>254<\/b>, 8\u201310 (2023)."},{"key":"40","unstructured":"40) Fujii H. Supply of domestic medical-use radionuclides. <i>Rinsho Hoshasen<\/i>, <b>68<\/b>, 947\u2013953 (2023), Japanese Journal of Clinical Radiology."},{"key":"41","unstructured":"41) Abe Y. \u201cJapan\u2019s NHI Drug Pricing System.\u201d: \u2039https:\/\/www.pmda.go.jp\/files\/000248690.pdf\u203a, accessed 8 April, 2026."},{"key":"42","unstructured":"42) MHLW. \u201cList of candidate components for supply-secured medicines (academic society recommendations): Materials for the subcommittee on the rapid and stable supply of prescription drugs (October 27, 2025).\u201d: \u2039https:\/\/www.mhlw.go.jp\/content\/10808000\/001586778.pdf\u203a, accessed 8 April, 2026."},{"key":"43","doi-asserted-by":"crossref","unstructured":"43) Araki Y, Momo K, Yasu T, Ono K, Uchikura T, Koinuma M, Sasaki T. Prescription pattern analysis for antibiotics in working-age workers diagnosed with common cold. <i>Sci. Rep.<\/i>, <b>11<\/b>, 22701 (2021).","DOI":"10.1038\/s41598-021-02204-3"},{"key":"44","unstructured":"44) Naruse M. OTC-like drugs should be classified as OTC drugs: it is essential to return from medical drugs to the starting point of prescription drugs. <i>JRI Research Journal<\/i>, <b>8<\/b>, 1\u201323 (2025)."},{"key":"45","unstructured":"45) MHLW. \u201c10th NDB Open Data: quantities by ATC category, age,and outpatient (out-of-hospital) prescriptions\u2014Internal medicines.\u201d: \u2039https:\/\/www.mhlw.go.jp\/stf\/seisakunitsuite\/bunya\/0000177221_00016.html\u203a, accessed 8 April, 2026."},{"key":"46","unstructured":"46) The Asahi Shimbun. \u201cDrug shortages continue in Japan as supply issues remain.\u201d: \u2039https:\/\/www.asahi.com\/articles\/DA3S15809400.html\u203a, accessed 8 April, 2026."},{"key":"47","unstructured":"47) MHLW. \u201cReview of stable supply medicines (request forcooperation from academic societies).\u201d: \u2039https:\/\/www.jsre.org\/uploads\/files\/info\/250117%20irai%20kourousyou.pdf\u203a, accessed 8 April, 2026."},{"key":"48","doi-asserted-by":"crossref","unstructured":"48) Metlay JP, Waterer GW, Long AC, Anzueto A, Brozek J, Crothers K, Cooley LA, Dean NC, Fine MJ, Flanders SA, Griffin MR, Metersky ML, Musher DM, Restrepo MI, Whitney CG. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. <i>Am. J. Respir. Crit. Care Med.<\/i>, <b>200<\/b>, e45\u2013e67 (2019).","DOI":"10.1164\/rccm.201908-1581ST"},{"key":"49","doi-asserted-by":"crossref","unstructured":"49) Fukuda D, Honda Y, Kayama Y, Fujii K, Kawamatsu S, Kawano Y, Vojtek I, Powell D, Mulgirigama A, Gu Y. The current landscape of antibiotic use and antimicrobial resistance in Japan: focusing on common infections including uncomplicated urinary tract infection and gonorrhea. <i>Antibiotics<\/i>, <b>14<\/b>, 813 (2025).","DOI":"10.3390\/antibiotics14080813"},{"key":"50","doi-asserted-by":"crossref","unstructured":"50) Stroobant EE, Kong S-H, Bencivenga M, Kinoshita T, Kim T-H, Sano T, de Manzoni G, Yang HK, Kitagawa Y, Strong VE. Korea, Japan, Europe, and the United States: why are guidelines for gastric cancer different? <i>Gastric Cancer<\/i>, <b>28<\/b>, 559\u2013568 (2025).","DOI":"10.1007\/s10120-025-01613-x"},{"key":"51","doi-asserted-by":"crossref","unstructured":"51) Rappuoli R, Alter G, Pulendran B. Transforming vaccinology. <i>Cell<\/i>, <b>187<\/b>, 5171\u20135194 (2024).","DOI":"10.1016\/j.cell.2024.07.021"},{"key":"52","doi-asserted-by":"crossref","unstructured":"52) Nakano T. Changes in vaccination administration in Japan. <i>Vaccine<\/i>, <b>41<\/b>, 2723\u20132728 (2023).","DOI":"10.1016\/j.vaccine.2023.03.020"},{"key":"53","doi-asserted-by":"crossref","unstructured":"53) Perlino C, Daniel H, Cadwallader AB. Which drugs should be on the essential medicines list? <i>AMA J. Ethics<\/i>, <b>26<\/b>, E282\u2013E288 (2024).","DOI":"10.1001\/amajethics.2024.282"},{"key":"54","doi-asserted-by":"crossref","unstructured":"54) Toshev A, Petkova-Gueorguieva E, Madzharov V, Mihaylova AA, Parahuleva N, Bogdanov G, Mirchev D, Gueorguiev S. Critical Medicines Act: analysis of the challenges and the path to health and pharmaceutical sustainability. <i>Farmatsiia<\/i>, <b>72<\/b>, 1\u20136 (2025).","DOI":"10.3897\/pharmacia.72.e175353"},{"key":"55","unstructured":"55) European Commission. \u201cProposal for a Critical Medicines Act.\u201d: \u2039https:\/\/health.ec.europa.eu\/document\/download\/a0d79c14-3702-459e-864b-67eb3bca6896_en?filename=mp_swd-2025-263_act_en.pdf\u203a, accessed 10 April, 2026."}],"container-title":["Biological and Pharmaceutical Bulletin"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00220\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,12]],"date-time":"2026-09-12T03:26:42Z","timestamp":1789183602000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/bpb\/49\/9\/49_b26-00220\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,10]]},"references-count":55,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"URL":"https:\/\/doi.org\/10.1248\/bpb.b26-00220","relation":{},"ISSN":["0918-6158","1347-5215"],"issn-type":[{"value":"0918-6158","type":"print"},{"value":"1347-5215","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,10]]},"article-number":"b26-00220"}}